PDCD1 and breast carcinoma: Notably, systemic SLR-loaded nanoparticle administration enhanced the infiltration of CD8+ and CD4+ T-cells into breast cancer tissue, enhancing the effects of administered antibodies against programmed cell death protein-1, generally known as PD-1.